Intuitive Surgical (NASDAQ:ISRG) shares staged a notable rebound on Thursday, climbing 4.7% to $421.42 as of 1:46 p.m. EDT. The rally added approximately $6.9 billion to the company's market capitalization, but the stock still languishes about 30% below its 52-week high of $603.88, set on January 7. Since that peak, Intuitive has lost roughly $65.6 billion in market value, underscoring the steep decline that has yet to be fully reversed.
The session's gains saw Intuitive open at $409.81 and reach an intraday high of $423.30, recovering from Wednesday's close of $402.38. Despite the bounce, the stock remains well off its January peak, with the gap narrowing to about 30.2% from the earlier 33.37% deficit reported by MarketWatch. The broader market context showed a split between sectors: medical technology stocks broadly advanced, while technology shares faced headwinds. Boston Scientific (NYSE:BSX) rose 5.2%, Stryker (NYSE:SYK) added 4.4%, and Medtronic (NYSE:MDT) gained 4.3%. The iShares U.S. Medical Devices ETF (NYSEARCA:IHI) climbed 3.3%, reflecting broad sector strength. In contrast, the Invesco QQQ Trust (NASDAQ:QQQ), which tracks the Nasdaq-100, fell 2.3%, as tech heavyweights came under pressure.
The move comes ahead of a shortened trading week, with the Nasdaq closed on July 3 for the Independence Day holiday. Thursday thus marked the final full session before the break, adding some urgency to positioning. Intuitive's next major catalyst is its second-quarter earnings call, scheduled for July 16 at 1:30 p.m. PDT, according to the company's investor relations site. Analysts and investors will be closely watching procedure volume numbers and da Vinci 5 system placements, given that nearly a third of the stock's value has been wiped out since January.
Valuation and Earnings Outlook
Intuitive Surgical currently trades at about 51 times trailing earnings, based on recent quote data. Looking forward, the stock carries a forward price-to-earnings ratio of 37.3, with a consensus analyst target of $565.08 over the next year. That implies roughly 34% upside from Thursday's price, or about 40% from Wednesday's close. The valuation story has become a key point of debate, as the stock's decline has widened the gap between current price and analyst expectations.
The company's first-quarter results provided some ammunition for bulls. Revenue jumped 23% year-over-year to $2.77 billion, while combined da Vinci and Ion procedure volumes rose approximately 17%. Intuitive placed 431 da Vinci systems during the quarter, including 232 of the newer da Vinci 5 models. CEO Dave Rosa described the quarter as showing "expanded adoption" for the company's da Vinci, Ion, and digital platforms. However, CFO Jamie Samath cautioned during the April earnings call that "revenue growth ahead of total procedure growth" was primarily driven by da Vinci 5, but warned that higher oil and memory prices could weigh on results later in the year.
Guidance and Tariff Risks
For the full year 2026, Intuitive expects da Vinci procedure growth worldwide in the range of 13.5% to 15.5%. The company is guiding for non-GAAP gross margin of 67.5% to 68.5% of revenue, which incorporates a 1.0% impact from tariffs. Management has indicated that additional tariffs could have a material effect on 2026 financial performance, adding another layer of uncertainty for investors.
The broader medical technology sector's strength on Thursday suggests a rotation into defensive names, as tech stocks faltered. With the Independence Day holiday approaching, trading volumes may be thinner, but the focus remains on Intuitive's upcoming earnings and whether the company can deliver on its growth targets to justify a rebound from current levels.
